Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Cash to Debt No Debt
ONCY's Cash to Debt is ranked higher than
89% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. ONCY: No Debt )
ONCY' s 10-Year Cash to Debt Range
Min: 45.91   Max: No Debt
Current: No Debt

Interest Coverage No Debt
ONCY's Interest Coverage is ranked higher than
70% of the 447 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ONCY: No Debt )
ONCY' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: -11.68
M-Score: -3.29
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
ROE (%) -93.47
ONCY's ROE (%) is ranked higher than
58% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -25.77 vs. ONCY: -93.47 )
ONCY' s 10-Year ROE (%) Range
Min: -164.19   Max: -26.92
Current: -93.47

-164.19
-26.92
ROA (%) -77.24
ONCY's ROA (%) is ranked higher than
56% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -19.98 vs. ONCY: -77.24 )
ONCY' s 10-Year ROA (%) Range
Min: -125.21   Max: -25.07
Current: -77.24

-125.21
-25.07
ROC (Joel Greenblatt) (%) -4336.23
ONCY's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -210.62 vs. ONCY: -4336.23 )
ONCY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -15749.15   Max: -250.97
Current: -4336.23

-15749.15
-250.97
EBITDA Growth (%) -4.40
ONCY's EBITDA Growth (%) is ranked higher than
78% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. ONCY: -4.40 )
ONCY' s 10-Year EBITDA Growth (%) Range
Min: -7.2   Max: 42.6
Current: -4.4

-7.2
42.6
EPS Growth (%) -10.50
ONCY's EPS Growth (%) is ranked higher than
75% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. ONCY: -10.50 )
ONCY' s 10-Year EPS Growth (%) Range
Min: -10.5   Max: 21.9
Current: -10.5

-10.5
21.9
» ONCY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ONCY Guru Trades in Q3 2013

Jim Simons 31,500 sh (unchged)
Jean-Marie Eveillard 427,200 sh (-5.07%)
» More
Q4 2013

ONCY Guru Trades in Q4 2013

Jean-Marie Eveillard 427,200 sh (unchged)
Jim Simons 19,200 sh (-39.05%)
» More
Q1 2014

ONCY Guru Trades in Q1 2014

Jim Simons 23,600 sh (+22.92%)
Jean-Marie Eveillard 427,200 sh (unchged)
» More
Q2 2014

ONCY Guru Trades in Q2 2014

Jim Simons 36,000 sh (+52.54%)
Jean-Marie Eveillard 188,600 sh (-55.85%)
» More
» Details

Insider Trades

Latest Guru Trades with ONCY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-06-30 Reduce -55.85%$1.23 - $1.99 $ 0.48-66%188600
Jean-Marie Eveillard 2013-03-31 New Buy$2.99 - $4.67 $ 0.48-87%450000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.89
ONCY's P/B is ranked higher than
80% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. ONCY: 2.89 )
ONCY' s 10-Year P/B Range
Min: 0.58   Max: 12.09
Current: 2.89

0.58
12.09
EV-to-EBIT -1.19
ONCY's EV-to-EBIT is ranked higher than
74% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ONCY: -1.19 )
ONCY' s 10-Year EV-to-EBIT Range
Min: -36.1   Max: 0.5
Current: -1.19

-36.1
0.5
Current Ratio 5.34
ONCY's Current Ratio is ranked higher than
80% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. ONCY: 5.34 )
ONCY' s 10-Year Current Ratio Range
Min: 2.21   Max: 142.02
Current: 5.34

2.21
142.02
Quick Ratio 5.34
ONCY's Quick Ratio is ranked higher than
81% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. ONCY: 5.34 )
ONCY' s 10-Year Quick Ratio Range
Min: 2.21   Max: 142.02
Current: 5.34

2.21
142.02

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.06
ONCY's Price/Net Cash is ranked higher than
95% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 125.18 vs. ONCY: 3.06 )
ONCY' s 10-Year Price/Net Cash Range
Min: 2.44   Max: 24.08
Current: 3.06

2.44
24.08
Price/Net Current Asset Value 3.06
ONCY's Price/Net Current Asset Value is ranked higher than
95% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 57.00 vs. ONCY: 3.06 )
ONCY' s 10-Year Price/Net Current Asset Value Range
Min: 2.44   Max: 24.08
Current: 3.06

2.44
24.08
Price/Tangible Book 2.89
ONCY's Price/Tangible Book is ranked higher than
89% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 8.79 vs. ONCY: 2.89 )
ONCY' s 10-Year Price/Tangible Book Range
Min: 2.06   Max: 22.36
Current: 2.89

2.06
22.36
Earnings Yield (Greenblatt) -84.00
ONCY's Earnings Yield (Greenblatt) is ranked lower than
187% of the 312 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. ONCY: -84.00 )
ONCY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 182.5   Max: 2127.2
Current: -84

182.5
2127.2
Forward Rate of Return (Yacktman) -46.83
ONCY's Forward Rate of Return (Yacktman) is ranked higher than
62% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: -9.72 vs. ONCY: -46.83 )
ONCY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -64.8   Max: 10.5
Current: -46.83

-64.8
10.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ONC.Canada, ONY.Germany
Oncolytics Biotech, Inc., was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd. The Company is a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers. It focuses its research and development efforts on the development of REOLYSIN, its potential cancer therapeutic. REOLYSIN is developed from the reovirus.
» More Articles for NAS:ONCY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Nasdaq stocks posting largest volume increases Oct 24 2014
Oncolytics Biotech® Inc. Announces Entry Into $20 Million "At-The-Market" Equity Distribution... Oct 24 2014
Oncolytics Biotech® Inc. Announces Entry Into $20 Million "At-The-Market" Equity Distribution... Oct 24 2014
Oncolytics Biotech® Inc. Announces Entry Into $20 Million "At-The-Market" Equity Distribution... Oct 24 2014
Merrimack Pharmaceuticals (MACK) Looks Strong: Stock Up 8.6% Oct 24 2014
Oncolytics Biotech® Inc. Announces Amendment to Common Share Purchase Agreement with Lincoln Park... Oct 20 2014
Oncolytics Biotech® Inc. Announces Amendment to Common Share Purchase Agreement with Lincoln Park... Oct 20 2014
Oncolytics Biotech® Inc. Announces Amendment to Common Share Purchase Agreement with Lincoln Park... Oct 20 2014
Oncolytics Biotech downgraded by Stifel Sep 17 2014
Oncolytics Biotech® Inc. Announces Overall and KRAS-Mutated Patient Data from U.S. Randomized Phase... Sep 16 2014
Oncolytics Biotech® Inc. Announces Overall and KRAS-Mutated Patient Data from U.S. Randomized Phase... Sep 16 2014
/C O R R E C T I O N from Source -- Oncolytics Biotech Inc./ Sep 03 2014
/C O R R E C T I O N from Source -- Oncolytics Biotech Inc./ Sep 03 2014
Media Advisory - Oncolytics Biotech® Inc. to Participate in the Baird 2014 Health Care Conference Sep 02 2014
Media Advisory - Oncolytics Biotech® Inc. to Participate in the Baird 2014 Health Care Conference Sep 02 2014
Oncolytics Biotech® Inc. Announces Second Quarter 2014 Results Aug 07 2014
Oncolytics Biotech® Inc. Announces Second Quarter 2014 Results Aug 07 2014
Oncolytics Up on Patient Enrolment Completion Jul 11 2014
Oncolytics (ONCY) Shares March Higher, Can It Continue? Jul 08 2014
Oncolytics Biotech Inc. (ONCY) in Focus: Stock Rises 9.5% Jul 08 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK